Maxigen Biotech (TPE:1783) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1783 Maxigen Biotech Inc TPE:1783
88 GF Score
Price NT$36.70
GF Value NT$58.52
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Maxigen Biotech  (TPE:1783) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Maxigen Biotech Cyclically Adjusted PB Ratio Related Terms


Maxigen Biotech Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech Cyclically Adjusted PB Ratio Chart

Maxigen Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.89 3.52 3.61 3.52 2.93

Maxigen Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 3.20 2.99 2.88 2.61

TPE:1783 vs ISRG, BDX, RMD: Cyclically Adjusted PB Ratio Comparison

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Cyclically Adjusted PB Ratio falls into.


TPE:1783
88GF Score
Maxigen Biotech Inc TPE:1783
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Maxigen Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Maxigen Biotech's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=16.711/333.9520*333.9520
=16.711

Current CPI (Jun. 2026) = 333.9520.

Maxigen Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201609 9.623 241.428 13.311
201612 9.739 241.432 13.471
201703 9.597 243.801 13.146
201706 9.706 244.955 13.232
201709 9.799 246.819 13.258
201712 9.648 246.524 13.070
201803 9.945 249.554 13.308
201806 10.188 251.989 13.502
201809 10.409 252.439 13.770
201812 10.507 251.233 13.966
201903 10.591 254.202 13.914
201906 10.273 256.143 13.394
201909 10.518 256.759 13.680
201912 10.611 256.974 13.790
202003 10.738 258.115 13.893
202006 10.320 257.797 13.369
202009 10.471 260.280 13.435
202012 10.722 260.474 13.747
202103 10.992 264.877 13.859
202106 11.259 271.696 13.839
202109 12.653 274.310 15.404
202112 12.838 278.802 15.377
202203 13.107 287.504 15.225
202206 13.527 296.311 15.245
202209 14.048 296.808 15.806
202212 14.569 296.797 16.393
202303 15.110 301.836 16.718
202306 14.801 305.109 16.200
202309 15.395 307.789 16.704
202312 15.305 306.746 16.662
202403 15.212 312.332 16.265
202406 14.939 314.175 15.879
202409 14.984 315.301 15.870
202412 15.423 315.605 16.320
202503 16.483 319.799 17.212
202506 15.754 322.561 16.310
202509 16.431 324.800 16.894
202512 17.145 324.054 17.669
202603 18.137 330.213 18.342
202606 16.711 333.952 16.711

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$36.70 is trading 37.3% below its estimated GF Value™ of NT$58.52. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: NT$58.52 vs. price of NT$36.70 (37.3% below fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
88GF Score

Get the complete analysis for TPE:1783

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$36.70
Price
NT$58.52
GF Value